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ASSESSMENT PROCEDURES
The extremity function index (EFI), a disability severity measure for neuromuscular
diseases: psychometric evaluation
Isa€ac Bosa, Klaske Wyniaa,b, Gea Drosta, Josue Almansab and Jan B. M. Kuksa
aDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; bDepartment of
Community and Occupational Health, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
ABSTRACT
Objective: To adapt and to combine the self-report Upper Extremity Functional Index and Lower
Extremity Function Scale, for the assessment of disability severity in patients with a neuromuscular disease
and to examine its psychometric properties in order to make it suitable for indicating disease severity in
neuromuscular diseases.
Design: A cross-sectional postal survey study was performed among patients diagnosed with a neuromus-
cular disease.
Methods: Patients completed both adapted extremity function scales, questionnaires for psychometric
evaluation, and disease-specific questions. Confirmatory factor analysis was performed, and reliability and
validity were examined.
Results: Response rate was 70% (n¼ 702). The Extremity Function Index model with a two-factor struc-
ture – for upper and lower extremities – showed an acceptable fit. The Extremity Function Index scales
showed good internal consistency (alphas: 0.97–0.98). The known-groups validity test confirmed that
Extremity Function Index scales discriminate between categories of “Extent of limitations” and “Quality of
Life.” Convergent and divergent validity tests confirmed that Extremity Function Index scales measure the
physical impact of neuromuscular diseases. Relative validity tests showed that the Extremity Function
Index scales performed well in discriminating between subgroups of patients with increasing “Extent of
limitations” compared to concurrent measurement instruments.
Conclusion: The Extremity Function Index proved to be a sound and easy to apply self-report disability
severity measurement instrument in neuromuscular diseases.
 IMPLICATIONS FOR REHABILITATION
 The Extremity Function Index reflects the functioning of all muscles in the upper and lower extrem-
ities involved in activities of daily living.
 The Extremity Function Index is an easy to administer and patient-friendly disability severity measure-
ment instrument that has the ability to evaluate differences in disability severity between relevant
neuromuscular disease subgroups.
 The Extremity Function Index is a valid and reliable disability severity measurement instrument for
neuromuscular diseases.
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Introduction
Neuromuscular diseases (NMDs) generally lead to progressive
impairment in body functions and therefore have a profound
impact on physical and psychosocial life, with loss of mobility as
one of the main problems [1,2]. Research into therapeutic
approaches to neuromuscular disorders has progressed rapidly
over the past decade and shows great promise for the future [3].
Therefore, easy to apply and psychometrically sound assessment
tools for evaluating disease severity or impairments in body func-
tions are of growing importance.
Currently, the evaluation of disease severity in NMDs is mainly
achieved by assessing muscle power functioning using electro-
myography, measuring muscle strength using handheld dyna-
mometry or by manual muscle tests. However, such tests can be
experienced as harmful and time consuming and do not reflect
the subject’s functional abilities [4]. In addition, there are observa-
tion-based measurements for NMD – as for example the Motor
Function Measure scale [4], and the disease-specific Muscular
Dystrophy Functional Rating Scale [5], but these measurements
require patient exercise, a physiotherapy room and trained investi-
gators. In order to overcome these disadvantages, self-report
measuring instruments were developed, for example the disease-
specific Amyotrophic Lateral Sclerosis Functional Rating Scale [6,7],
measuring instruments administered by trained evaluators such as
the Muscular Dystrophy Functional Rating Scale [5], and a meas-
urement of activity limitations the ACTIVLIM [8], a combination
questionnaire for children and adults. However, some of these
instruments are disease-specific, evaluator-dependent or limited in
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feasibility. Also generic health-related quality-of-life (QoL) meas-
urements – the SF-36, for example – are used to measure the
impact of disabilities on QoL [2]. Unfortunately, these generic
measurements do not have specific items relevant for patients
with a NMD, and therefore lacking sensitivity to change, while
some of these items will be redundant when applied to NMDs [1].
A well-known and commonly used disability-severity score, in
clinical practice often used as indicator for disease severity, is the
Expanded Disability Scale (EDSS) developed for patients with mul-
tiple sclerosis [9]. This disability-severity score is based on limita-
tions in mobility. The biggest advantages of the self-report
version of the EDSS are that: (1) it is an easy instrument to admin-
ister in clinical practice and research and (2) it expresses disability
severity in terms of a number, so that a change in disability sever-
ity can easily be evaluated [10], For these reasons, we opted for
limitations in mobility as a starting point for the development of a
disability-severity measurement in NMDs that can serve as an indi-
cator for disease-severity. This seems to be appropriate as it is
known that muscle function related limitations in activities in
NMDs are regarded as indicators of disease severity [11,12].
In summary, a valid and reliable, easy to administer, self-report
disability-severity measurement instrument for adults, reflecting the
functioning of muscles in the upper and lower extremities involved
in activities of daily living covering NMDs is not available yet.
Therefore, the aim of this study was to adapt and to combine two
validated self-report questionnaires, the Upper Extremity Functional
Index [13] (UEFI) and the Lower Extremity Functional Scale [14]
(LEFS) as a disability severity measurement instrument in NMDs.
Patients and methods
Sample
A cross-sectional postal survey study was conducted among
patients diagnosed with an NMD (n¼ 1003). These patients were
registered at the Department of Neurology of the University Medical
Center Groningen, the Netherlands. The sample comprised patients
from the four major NMD groups according to Rowland: motor neu-
ron disorders, muscle disorders, junction disorders, and peripheral
nerve disorders [15]. Patients were included if they could be
assigned to one of these four NMD groups. Furthermore, patients
also had to be aged 18 years or older, be able to read and write in
Dutch, and able to provide informed consent.
Procedure
Patients received information about the study and were invited to
participate. Patient’s informed consent was achieved by returning
the completed questionnaire. Respondents completed both
(adjusted) extremity function scales, questionnaires for psychomet-
ric evaluation, and answered demographic and disease-specific
questions. Reminders were sent after two weeks. After the question-
naires had been returned, they were checked for completeness. If a
page had not been completed, a copy was returned with a request
to complete the missing questions or, if this only concerned one or
a few questions, patients were interviewed by telephone.
The Medical Ethical Committee of the University Medical
Center of Groningen has assessed the study proposal and con-
cluded that approval was not required (Reference METc2009.310).
Extremity functioning index
The self-report Upper Extremity Functional Index (UEFI) and Lower
Extremity Functional Scale (LEFS) were used as a basis for the
disability-severity measure, the Extremity Functioning Index. Both
scales were developed and validated for easy assessment of (limi-
tations in) functioning. Each scale consists of 20 items assessing
functional problems. Items were scored on a 5-point scale with
discrete responses ranging from 0 (extremely difficult or unable to
perform activity) to 4 (no difficulty). Items for both scales were
summed for a total score ranging from 0 to 80 points, with higher
scores representing higher levels of functioning. In previous stud-
ies, both scales showed good internal consistency (Cronbach’s
alphas: 0.90 [16] and 0.96 [14] for the LEFS, and 0.95 [13] for the
UEFI), and stability (ICCs: 0.88 [17] and 0.97 [18] for the LEFS, and
0.85 [19] for the UEFI).
For the purpose of this study, the LEFS and the UEFI were
translated into Dutch following the procedure proposed by
Guillemin et al. [20]. First, the original Canadian English version
was translated into Dutch by three researchers (IB, KvdB and HB)
who have a working command of Dutch and English at academic
level and who worked independently of each other. Secondly, the
most satisfactory translation was chosen by consensus among the
researchers. Thirdly, this Dutch translation was translated back
into English by a native English speaker. Finally, the resulting
English version was compared to the original English version, and
all discrepancies were discussed by the three researchers. Any
remaining discrepancies were discussed with the native English
speaker.
The translated version of the LEFS and UEFI was reviewed by
three medical specialists in NMDs (JBMK, GD and IB) and a meth-
odologist (BM) on clarity, applicability and patient burden. As a
result, six questions in the LEFS were adjusted for reasons of
applicability in NMD patients concerning disease-specific limita-
tions to walking distance (questions 11 and 12), sitting time (ques-
tion 14), running (questions 16 and 17) and hopping (question
19). These questions were adjusted to shorter distances (questions
11 and 12), shorter duration (question 14), walking (questions 16
and 17) and jumping (question 19). Because of these disease-spe-
cific adjustments, we have renamed the LEFS into the Lower
Extremity Functional Index (LEFI). Next, the feasibility of the UEFI
and LEFI was examined by pre-testing in a sample of twenty ran-
domly selected NMD-patients. No barriers or unclear and ambigu-
ous items were found. For the UEFI, the LEFI and the combination
of both scales, the EFI, item scores were transformed for both sub-
scales (score range from 0 to 80) and the total scale (score range
from 0 to 160) into index scales with scores ranging from 0 (not
difficult) to 100 (extremely difficult).
Measurement instruments
To examine the psychometric properties of the EFI, the following
measurement instruments were applied:
The Neuromuscular Disease Impact Profile (NMDIP), a broad
and generic ICF-based disease impact measurement instrument
that includes 36 items and consists of eight scales and four add-
itional items [21]. The 36 items represent the four ICF compo-
nents. For the Body Functions component items and for the
Participation component items scoring options ranged from 0 (no
disability) to 4 (complete disability); for the Activities component
items scoring options ranged from 0 (no disability) to 3 (complete
disability); and for the Environmental Factors component items
scoring options ranged from 0 (no support) to 2 (full support).
Item scores were summed into a scale, with higher scores indicat-
ing more disability. In a previous study among Dutch NMD
patients, the NMDIP domains showed satisfactory levels of internal
consistency: Cronbach’s alpha ranged from 0.63 to 0.92 and Mean
Inter-item Correlation Coefficient from 0.47 to 0.77 [21].
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The Medical Outcome Study 36-item Short Form Health Survey
(SF-36) is a broad and generic Health-Related Quality Of Life
(HRQoL) measurement and consists of 36 items divided over eight
domains [22]. For each domain, item scores were coded, summed,
and transformed on a scale from 0 (worst health) to 100 (best
health). In a previous study among Dutch multiple sclerosis
patients, the SF-36 domains showed satisfactory levels of internal
consistency: Cronbach’s alpha ranged from 0.81 to 0.94 [21].
The Groningen Activity Restriction Survey (GARS) is a domain-
specific instrument for measuring Limitation in activities and con-
sists of 18 items divided over two scales [23]. A four-category
response format was used, ranging from 1 (no problem in per-
forming without help) to 4 (impossible to perform). Scores were
summed for each subscale. The GARS showed strong levels of
internal consistency in a study among Dutch NMD patients:
Cronbach’s alphas were 0.93 and 0.95 [21].
Single item variables
The first variable “Extent of Limitations” was evaluated with
the Extent of Limitations Visual Analogue Scale (VAS) [24]
Respondents were asked to answer the question: “To what extent
are you limited due to your NMD?” Scoring options ranged from 0
(no limitation at all) to 10 (most severely limited). The second vari-
able “Quality of Life” (QoL) was adapted from the WHOQOL-bref
[25]. Respondents were asked to answer the question: “How
would you rate your quality of life?” Response options were:
1¼ very poor, 2¼ poor, 3¼neither poor nor good, 4¼good and
5¼ very good.
Analysis
Descriptive statistics were used for describing the patient
characteristics.
To construct the EFI, we hypothesized a two-factor model in
which extremity functioning is measured within domains for
upper extremity functioning (using items from the UEFI) [13] and
lower extremity functioning (using items from the LEFI) [14].
Before testing the two-factor model, the data were examined for
the presence of univariate (standardized scores: jzj3.30) and
multivariate outliers (Mahalanobis Distance: p< 0.001) [26,27].
Next, to test the two-factor model a confirmatory factor analysis
(CFA) was conducted using M-Plus 7.1 [28]. The CFA methods
used in this software are suitable for not normally distributed
ordinal items and are based on polychoric correlations between
standardized observed ordinal items [29]. Factor loadings of >0.40
were considered sufficient [30]. Model fit was examined using
multiple criteria: (1) as a measure of overall fit, the root means
squared error of approximation (RMSEA): 0.05 indicate a close
fit, whereas values up to 0.08 indicate an adequate fit; and (2) as
descriptive measures: a Comparative Fit Index (CFI) 0.95 and a
Tucker–Lewis Index (TLI) 0.95 indicate an adequate fit [31] To
merge the two domains into one disability-severity measurement,
a strong correlation was expected (Spearman’s correlation coeffi-
cient 0.70). For scale construction, the maximum number of
missing items allowed to be replaced by the mean scale score
was determined by a sufficient Cronbach’s alpha in relation to the
number of scale items [32].
Next the EFI scale features were examined. The internal consist-
ency was examined using Cronbach’s alpha. Alpha was considered
sufficient if 0.70 [33,34]. The distribution of scale scores was
evaluated by calculating the median, mean, standard deviation,
and the observed score range. Floor and ceiling effects were
examined by calculating the proportions of patients with worst
and best possible scores. Proportions 20% were considered
acceptable [35].
For examining psychometric properties, the Kruskal–Wallis test
and the Mann–Whitney U-test were used for not normally distrib-
uted variables (Shapiro–Wilk test, p< 0.05).
Regarding known-groups validity [36,37], we hypothesized that
the EFI scales should discriminate between respondent subgroups
known to differ on relevant clinical characteristics. The variables
“Extent of Limitations” and “Quality of Life” were used to create
such relevant respondent subgroups. Respondents were divided
into two groups of “Extend of Limitations”: those with a lower
“Extent of Limitations” (score 0–4) and those with a higher “Extent
of Limitations” (score 5–10). Respondents were divided into
two groups of “Quality of Life”: those with a poor “Quality of Life”
(response options 1–3) and those with good Quality of Life
(response options 4–5).
Convergent and divergent validity was performed by examin-
ing the extent to which correlation values between EFI scales
and concurrent measures were consistent with hypotheses. The
Spearman rank order correlation coefficient (Rho, p, 2-tailed)
was calculated between the EFI scales and concurrent scales. To
support convergent validity, the EFI scales needed to have
strong correlations (0.70), with scales covering the same
domain in concurrent measurements (physical functioning scale
and activity scales) [38]. To support the divergent validity, the
EFI scales should correlate weakly ( 0.40) with scales covering
different domains (mental health scale) in concurrent measure-
ments [38].
Relative validity (RV) indicates the extent to which a scale or
construct is able to discriminate between groups compared to the
concurrent measures [22,39]. Respondents were divided into four
groups of “Extent of Limitations”: Group A with a “No to low
extent of limitation” (score 0–4), Group B with a “moderate extent
of limitation” (score 5–6), Group C with a “high extent of limi-
tation” (score 7–8) and, Group D with a “very high extent of limi-
tation” (score 9–10). Next, RV of scales was examined in several
steps. First, the Chi-square was computed for each scale by calcu-
lating the Kruskal–Wallis H-test. Second, the RV of each scale was
computed by dividing each H-ratio by the H-ratio for the scale
with the highest H-ratio, and multiplied by one hundred.
To estimate the magnitude of the clinical relevance of statistic-
ally significant group differences, the nonparametric effect size
(coefficient r) for unrelated samples was calculated [38]. The coef-
ficient r was calculated by dividing the Z-statistic (obtained from
the Mann–Whitney U-test) by the root of the sample size (n). To
interpret these nonparametric effect sizes, Cohen suggests the fol-
lowing thresholds for interpretation: r< 0.10 indicates a trivial
effect; r 0.10 to <0.24 a small effect; r 0.24 to <0.37 a moder-
ate effect; and r 0.37 a large effect. An r 0.10 reflects a clinic-
ally relevant difference between groups [38,40].
Statistical analyses were performed using SPSS 23.0 for
Windows and CFA was performed using M-Plus 7.1 (Los Angeles,
CA).
Results
Patient characteristics
In sum, 702 patients (70% response rate) completed the question-
naires. The participants’ demographic and disease-specific charac-
teristics are described in Table 1. Mean age of participants was
59 years (SD¼ 15.7), the mean number of years since diagnosis
was 12 years, and about 30% of the respondents had retired due
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to an NMD. The motor neuron disorder group was relatively small
compared to the other NMD subgroups (Rowland classification).
Nonrespondents did not differ from respondents in terms of
gender but were statistically significant younger (p values: 0.000,
2-sided) than respondents.
Extremity function index (EFI) structure
CFA confirmed the expected two-factor model with good loadings
(Table 2). Each observed aspect in terms of use of lower or upper
extremities, loaded sufficiently on the expected factor. Model fit
indicators were sufficient with RMSEA 0.086 (90% confidence
interval: 0.084–0.089), CFI 0.96, and TLI 0.96 and confirmed a good
fit of the two-factor model using the Upper Extremity Functional
Index (UEFI) and the Lower Extremity Functional Index (LEFI). As
expected, the correlation between the UEFI and LEFI was strong
(0.87), such that both functioning domains can be merged into
one disability-severity measure.
Scale features
Table 3 shows the scale features for the Extremity Function Index
(EFI) total scale and EFI subscales for the total sample and for the
four major NMD groups. Internal consistency for the EFI and both
of the subscales was good. Cronbach’s alphas ranged from 0.97 to
0.98. No negative floor and ceiling effects were found.
The final version of the EFI scale consists of two subscales each
with twenty items, and also a total scale score can be calculated
(appendix).
Known-groups validity
The known-groups validity of the EFI scales was confirmed by the
expected group differences (Table 4). Patients classified as having
greater “Extent of Limitations” or higher “Quality of Life” had sig-
nificantly higher scores on the EFI scales compared with those
classified as having lower “Extent of Limitations” or lower reported
“Quality of Life”. Effect sizes were very large for “Extent of
Limitations” and moderate for “Quality of Life” and confirmed clin-
ical relevance.
Convergent and divergent validity
Table 5 summarizes our findings on the convergent and divergent
test of EFI scales. The direction, strength and pattern of correla-
tions are as hypothesized. We found the expected high correla-
tions for most of the similar constructs (bold figures in the table)
confirming convergent validity. Unexpected was the moderate
correlation with the NMDIP “Muscle Functions” variable. We found
the expected low correlations (italic figures in the table) support-
ing divergent validity. Unexpected were the moderate correlations
with the NMDIP “Mental Functions and Pain” variable.
Relative validity (RV)
About 40% (n¼ 278) of the respondents reported “low extent of
limitations” (Group A) due to NMD, while 24% (n¼ 169) reported
Table 2. Factor loadings of the extremity function index (EFI) model.
Factor
Upper Extremity Function Index
1 Any of the activities involved in your usual work, housework,
or schoolwork
0.860
2 Your usual hobbies, and recreational or sporting activities 0.766
3 Lifting a bag of groceries to waist level 0.928
4 Lifting a bag of groceries above your head 0.900
5 Grooming your hair 0.829
6 Pushing up on your hands (e.g., from bathtub or chair) 0.855
7 Preparing food (e.g., peeling, cutting) 0.861
8 Driving 0.755
9 Vacuuming, sweeping, or raking 0.920
10 Dressing 0.915
11 Buttoning your clothing 0.839
12 Using tools or appliances 0.871
13 Opening doors 0.867
14 Cleaning 0.919
15 Tying or lacing shoes 0.883
16 Sleeping 0.494
17 Laundering clothes (e.g., washing, ironing, folding) 0.884
18 Opening a jar 0.810
19 Throwing a ball 0.846
20 Carrying a small suitcase (with your affected limb) 0.889
Lower Extremity Function Index
1 Any of the activities involved in your usual work, housework,
or schoolwork
0.897
2 Your usual hobbies, and recreational or sporting activities 0.809
3 Getting into or out of the bathtub 0.889
4 Walking between rooms 0.924
5 Putting on your shoes or socks 0.894
6 Squatting 0.886
7 Lifting an object, like a bag of groceries from the floor 0.914
8 Performing light activities around your home 0.928
9 Performing intensive activities around your home 0.927
10 Getting into or out of a car 0.873
11 Walking 10 yards 0.924
12 Walking 200 yards 0.897
13 Going up or down 10 stairs (about 1 flight of stairs) 0.897
14 Standing for 1 hour 0.859
15 Sitting for 1 hour 0.623
16 Running on even ground 0.886
17 Running on uneven ground 0.905
18 Making sharp turns while running fast 0.933
19 Jumping 0.943
20 Rolling over in bed 0.828
Table 1. Sample characteristics (n¼ 702).
Variables Total sample
Gender (%)
Female 350 (50.1)
Age
Median 61
IQR 21
Mean (SD) 58.9 (15.7)
Range 19–92
Year since diagnosis
Median 7
IQR 11
Mean (SD) 11.6 (11.0)
Range 0-65
Relationship status (%)
Married/partnership 497 (70.8)
Unmarried/widowed/divorced 186 (26.5)
Missing 19 (2.7)
Educational level (%)
Primary school/vocational training 235 (33)
Secondary school/vocational training 270 (38)
Higher education/vocational training 161 (23)
University 28 (4)
Employment status (more answers possible) (%)
Enrolled in a training program or educational course 36 (5.1)
Employment (part time or full time) 173 (24.6)
Voluntary work (part time or full time) 42 (6.0)
(Partially) retired due to NMD 213 (30.3)
Housewife/househusband 171 (24.4)
Retired due to age 243 (34.6)
NMD category (%)
Motor neuron disorder 43 (6.1)
Muscle disorder 154 (22.1)
Junction disorder 234 (33.3)
Peripheral nerve disorder 271 (38.5)
IQR: inter quartile range (Q3-Q1).
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a “moderate extent of limitation” (Group B), and 28% (n¼ 197)
reported a “high extent of limitation” (Group C). About 8%
(n¼ 58) of the respondents reported a “very high extent of limi-
tations” (Group D).
Comparisons of the RV coefficients, as summarized in Table 6,
revealed that the EFI “Lower Extremity Function Index” subscale
and the Extremity Function Index total scale were the most valid
in discriminating between groups with an increasing “Extent of
Limitation.”
We then examined the performance of the EFI in indicating
the differences between extreme groups (A–D) and subgroups
(A–B, B–C, C–D) regarding the physical functioning construct, as it
relates to the similar constructs in the concurrent measurement
instruments.
Regarding physical functioning, we found that the NMDIP
“Muscle Functions” performed slightly better compared to the
“Lower Extremity Function Index.” Subgroup differences (A–B, B–C
and C–D) were statistically significant and clinically relevant for all
EFI scales.
In summary, the EFI scales showed one small, and furthermore
large effect sizes in discriminating between (sub) groups with an
increasing “Extent of Limitations” compared to similar physical
functioning constructs in concurrent measures.
Discussion
The Extremity Function Index (EFI) appears to be a valid and reli-
able instrument for evaluating disability-severity in adult patients
Table 3. Scale features of the EFI total scale and subscales UEFI and LEFI (n¼ 702).
Sample and Scales Cases (n) Items (k) Possible score range Observed score range Floor effect (%) Ceiling effect (%) Median IQR Mean SD Alpha
Total
EFI 702 40 0-160 0-159 5.6 0.0 37 41 37.8 25.8 0.98
UEFI 701 20 0-80 0-79 9.1 0.0 31 42 33.9 25.7 0.97
LEFI 700 20 0-80 0-80 8.4 0.6 41 48 41.7 28.2 0.97
Motor neuron disorder
EFI 43 40 0-160 0-158 2.3 0.0 54 49 55.1 28.2 0.98
UEFI 43 20 0-80 0-79 2.3 0.0 49 47 52.4 27.9 0.97
LEFI 43 20 0-80 0-80 4.7 4.7 61 50 57.4 32.1 0.98
Muscle disorder
EFI 155 40 0–160 0–159 1.3 0.0 49 67 50.8 25.7 0.98
UEFI 154 20 0–80 0–79 3.2 0.0 44 40 46.1 26.4 0.97
LEFI 153 20 0–80 0–80 1.9 1.3 56 42 55.6 27.4 0.97
Junction disorder
EFI 234 40 0–160 0–143 11.5 0.0 23 37 26.9 22.4 0.98
UEFI 234 20 0–80 0–72 14.1 0.0 25 36 26.8 22.3 0.96
LEFI 234 20 0–80 0–71 17.1 0.0 23 40 27.0 24.1 0.97
Peripheral nerve disorder
EFI 270 40 0–160 0–152 3.7 0.0 36 37 37.1 23.3 0.98
UEFI 270 20 0–80 0–76 9.3 0.0 27 40 30.2 23.9 0.96
LEFI 270 20 0–80 0–76 5.2 0.0 44 38 44.0 25.2 0.97
EFI: extremity function index; IQR: inter quartile range (Q3-Q1); LEFI: lower extremity functional index; SD: standard deviation; UEFI: upper extremity functional index.
Table 4. Known-groups validity of the extremity function index (n¼ 702).
Low (0–4) versus high (5–10) extent of limitations Poor (1–3) versus good (4–5) quality of life
N Low/High
Low Mean
Rank
High Mean
Rank
p value
(Z-statistic)a
Effect
Size N Low/High
Poor Mean
Rank
Good Mean
Rank
p value
(Z-statistic)a Effect Size
Extremity
Function Index
278/424 216.4 440.1 0.000 (14.3) 0.54 228/474 453.8 302.3 0.000 (9.3) 0.35
Lower
Extremity
Function Index
278/422 215.3 439.6 0.000 (14.4) 0.54 228/472 443.1 305.8 0.000 (8.4) 0.32
Upper
Extremity
Function Index
278/423 230.5 430.3 0.000 (12.8) 0.48 228/473 453.1 301.8 0.000 (9.3) 0.35
aMann–Whitney U-test, 2-sided.
Table 5. Results of convergent and divergent validity of EFI total and subscales
(n¼ 702).
EFIa UEFIa LEFIa
NMDIP
Muscle functions 0.73 0.63 0.74
Movement functions 0.59 0.50 0.59
Swallowing and speech functions 0.31 0.35 0.25
Excretion and reproductive functions 0.46 0.44 0.42
Mental functions and pain 0.58 0.56 0.53
Activities of moving around 0.82 0.69 0.86
Self-care and domestic activities 0.85 0.83 0.80
Participation in life situations 0.64 0.56 0.64
SF-36
Physical functioning 20.89 20.76 20.92 
Social functioning 20.53 20.52 20.49
Role physical 20.51 20.49 20.47
Bodily pain 20.48 20.44 20.48
General health 20.58 20.55 20.53
Mental health 20.29 20.32 20.25
Role emotional 20.32 20.33 20.28
Vitality 20.49 20.52 20.42
GARS
Instrumental activities of daily living 0.89 0.83 0.86
Activities of daily living 0.86 0.77 0.87
aSpearman rank order correlation coefficient, all correlations are significant at
the 0.01 level (2-tailed).
EFI: Extremity Function Index; GARS: Groningen Activity Restriction Scale; LEFI:
Lower Extremity Functional Index; NMDIP: Neuromuscular Disease Impact Profile;
UEFI¼Upper SF-36: Medical Outcome Study Short Form Questionnaire;
Expected convergent validity scores (higher correlations >0.70) in bold and
expected divergent validity scores (lower correlations <0.40) in italic.
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with an NMD. The confirmed model for the EFI included a two-
factor structure with two one-dimensional scales with twenty indi-
cators in the upper extremity function domain and twenty indica-
tors in the lower extremity function domain. The reliability of the
EFI and both subscales was good. Known-groups validity was sup-
ported by statistically significant and clinically relevant differences
between groups of patients with a NMD that differed in terms of
“Extent of Limitations” and “Quality of Life”. Expectations regard-
ing the direction and strengths of the convergent and divergent
correlations were confirmed for most correlations. Unexpected
was the moderate correlation with the “Muscle Functions” vari-
able. Apparently loss of muscle strength is more obvious in lower
extremity function than in upper extremity function. Also unex-
pected were the moderate correlations with the NMDIP “Mental
Functions and Pain” variable. Probably, the aspect of pain in this
variable caused this stronger correlation with the EFI (sub)scales
than expected. Finally, compared to concurrent domain specific
and generic QOL measurement instruments the EFI performed
well in discriminating between groups of NMD patients with an
increasing “Extent of Limitations” as indicated on the visual analog
scale.
A major strength of this study lies in the large and representa-
tive study population representing the four major NMD groups
according to Rowland [15], which improves the generalizability of
the study results. As such the EFI may be considered applicable to
the broad range of NMD patients that are encountered in clinical
practice
A possible study limitation should be noted: the relatively small
sample size of the motor neuron disorder group compared to the
sample size of the other NMD groups. However, the complete
study sample showed good representation of functional
limitations in NMDs in terms of the use of upper and lower
extremities in daily activities.
The EFI can have important implications for multidisciplinary
care, research and for patients. Clinicians now have an easy to
administer and patient-friendly disability-severity measurement
instrument to evaluate the differences in disability-severity
between relevant subgroups of NMD patients. These differences
can be seen as an indicator for the ability of this measurement
instrument for detecting changes in disability over time.
Researchers also can compare disability-severity between groups
of NMD patients. EFI could also have implications for patient self-
management. For instance, EFI can offer patients a voice in mak-
ing future decisions about assistive equipment and environmental
adjustments.
Further research should focus on examining the relationship
between objective and subjective disease-severity, psychometric
evaluation concerning stability and sensitivity to change of the
EFI, and validation across other populations of neuromuscular dis-
ease patients in other cultures.
In conclusion, this study showed that the Extremity Function
Index (EFI) appears to be a reliable and valid disability-severity
measurement instrument for NMDs. Moreover, the measure is an
easy to administer and patient-friendly instrument for clinical
practice and can also support clinical trials and epidemiological
studies.
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Table 6. Relative validity (RV) of the EFI, disease specific, domain specific and generic measurement instruments compared, using subgroups of extent of limitations
(n¼ 702).
Group A No to
Low Extent of
Limitations
(score 0–4)
Group B Moderate
Extent of
Limitations
(score 5–6)
Group C High
Extent of
Limitations
(score 7–8)
Group D Very
high Extent of
Limitations
(score 9–10)
N Median (IQR) N Median (IQR) N Median (IQR) N Median (IQR) Chi Square RV A-B B-C C-D A-D
Extremity Function Index (EFI) 278 16 (28) 169 39 (28) 197 51 (29) 58 79 (30) 258.0 96 0.43 0.23 0.42 0.59
Lower Extremity Function Index (LEFI) 278 18 (33) 167 44 (31) 197 59 (34) 58 84 (26) 268.8 100 0.41 0.26 0.45 0.61
Upper Extremity Function Index (UEFI) 278 14 (27) 168 38 (31) 197 44 (34) 58 74 (43) 201.5 75 0.39 0.17 0.36 0.54
NMDIP
Muscle functions 249 25 (26) 161 50 (25) 192 50 (25) 56 75 (37) 244.6 91 0.40 0.26 0.43 0.63
Movement functions 235 8 (17) 140 17 (25) 170 25 (16) 49 42 (29) 141.2 53 0.29 0.20 0.29 0.51
Swallowing and speech functions 270 0 (0) 156 0 (13) 188 0 (25) 55 13 (25) 57.3 21 0.22 – 0.18 0.37
Excretion and reproductive functions 206 0 (17) 120 8 (25) 140 17 (31) 43 25 (25) 55.5 21 0.20 – – 0.37
Mental functions and pain 237 10 (15) 137 20 (20) 173 30 (25) 50 33 (25) 135.7 50 0.29 0.23 0.19 0.47
Activities of moving around 278 6 (17) 169 17 (22) 197 22 (28) 58 56 (34) 216.3 80 0.37 0.22 0.40 0.58
Self-care and domestic activities 277 4 (4) 169 17 (21) 197 29 (45) 58 75 (67) 254.6 95 0.41 0.25 0.40 0.61
Participation in life situations 276 0 (8) 168 8 (17) 196 17 (33) 55 33 (33) 189.1 70 0.26 0.29 0.28 0.60
SF-36
Physical functioning 277 25 (9) 169 19 (8) 197 16 (8) 58 11 (3) 254.7 95 0.39 0.26 0.44 0.61
Social functioning 278 9 (2) 169 8 (2) 196 7 (1) 58 6 (4) 130.6 49 0.27 0.19 0.21 0.43
Role physical 278 8 (3) 168 5 (4) 196 5 (2) 57 4 (2) 112.1 42 0.30 – – 0.41
Emotional functioning 278 6 (1) 167 6 (2) 196 6 (2) 57 4 (3) 33.0 12 0.18 – 0.16 0.28
Mental functioning 278 25 (4) 169 24 (5) 196 24 (4) 58 22 (7) 32.4 12 0.13 – 0.16 0.27
Vitality 278 17 (6) 169 15 (5) 196 14 (5) 58 11 (6) 101.4 38 0.25 0.13 0.23 0.41
General health 278 17 (6) 169 14 (5) 196 12 (5) 58 10 (5) 169.7 63 0.35 0.22 0.20 0.48
Bodily pain 278 55 (16) 169 44 (17) 197 39 (20) 58 33 (22) 91.5 34 0.23 0.16 0.18 0.39
GARS
Activities of daily living 278 11 (4) 169 15 (7) 197 18 (10) 58 27 (17) 213.3 79 0.37 0.21 0.40 0.60
Instrumental activities of daily living 277 8 (5) 169 13 (8) 195 16 (8) 58 24 (9) 225.8 83 0.40 0.17 0.40 0.60
GARS: Groningen Activity Restriction Scale; IQR: Inter Quartile Range (Q3-Q1); NMDIP: neuromuscular disease impact profile; SF-36: Medical Outcome study Short
Form Questionnaire.
EFI, NMDIP and GARS scales: higher scores¼worse health; –¼ not statistically significant
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